ACADIA Pharmaceuticals (ACAD)
In a report issued on February 28, Gregory Renza from RBC Capital maintained a Buy rating on ACADIA Pharmaceuticals, with a price target of $34.00. The company’s shares closed last Tuesday at $25.07.
According to TipRanks.com, Renza is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ACADIA Pharmaceuticals with a $29.53 average price target, implying a 21.8% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $36.00 price target.
Beam Therapeutics (BEAM)
RBC Capital analyst Luca Issi maintained a Hold rating on Beam Therapeutics on February 28 and set a price target of $85.00. The company’s shares closed last Tuesday at $73.50.
According to TipRanks.com, Issi has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Beam Therapeutics is a Strong Buy with an average price target of $126.25, which is a 62.3% upside from current levels. In a report issued on February 28, J.P. Morgan also maintained a Hold rating on the stock with a $110.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ACAD:
- Stifel Nicolaus Sticks to Their Hold Rating for Wendy’s (WEN)
- Kepler Capital Sticks to Their Hold Rating for Grifols SA (GRFS)
- Fabasoft AG (FBSFF) Receives a Buy from Warburg Research
- Barclays Sticks to Its Buy Rating for Sovos Brands (SOVO)
- Barclays Reaffirms Their Hold Rating on Beam Therapeutics (BEAM)